NCT06683963

Brief Summary

The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). The second-a structured programme to train and familiarise patients and caregivers to Rebee over patients' Community Hospital (CH) inpatient rehabilitation stay-adopts an evidence-based approach to increase uptake and adherence to Rebee.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 29, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 12, 2024

Completed
19 days until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2025

Completed
Last Updated

November 12, 2024

Status Verified

November 1, 2024

Enrollment Period

11 months

First QC Date

October 29, 2024

Last Update Submit

November 9, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks

    Modified Barthel Index (MBI) measures ability to complete activities of daily living (ADLs). Scores range from 0 to 100. A higher score represents more independence, a lower score indicates more assistance needed (ie less independent). 0-20: Total dependence, 21-60: Severe dependence, 61-90: Moderate dependence, 91-99: Slight dependence, 100: Independence.

    from recruitment (week 0) till end of study at 12 weeks

Secondary Outcomes (6)

  • Change in Quality of Life scores from baseline to 4, 8, and 12 weeks

    from recruitment (week 0) till end of study at 12 weeks

  • Change in Patient Activation Level from baseline to 4, 8, and 12 weeks

    from recruitment (week 0) till end of study at 12 weeks

  • Readmission rates to hospital within 30 days of discharge

    within 30 days from discharge date

  • Change in Joint range of motion from baseline to 4, 8, and 12 weeks

    from recruitment (week 0) till end of study at 12 weeks

  • Length of Stay in Community Hospital reported in days

    From recruitment (week 0) till end of study at 12 weeks

  • +1 more secondary outcomes

Study Arms (2)

Control - usual care

NO INTERVENTION

Business as usual in community hospital, no added device intervention

Intervention - Rebee

EXPERIMENTAL

Addition of Rebee device during and after community hospital stay

Device: Rebee

Interventions

RebeeDEVICE

Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge

Intervention - Rebee

Eligibility Criteria

Age60 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Rehabilitation Diagnostic Group (RDG): Total Knee Replacement / Deconditioning
  • Age 60 and above
  • Speak English/Mandarin
  • Able to follow instructions, no cognitive impairment
  • No MDRO (MultiDrug Resistant Organism)
  • Suitable and able to wear motion sensor on upper and lower limbs
  • Suitable and able to engage in Rebee exercises

You may not qualify if:

  • Not under RDG: Total Knee Replacement / Deconditioning
  • Below 60 years old
  • Unable to speak English/Mandarin
  • Cognitive impaired, unable to follow instructions
  • Has MDRO
  • Not suitable to wear motion sensor on upper and lower limbs
  • Refusal to participate / give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
A/Prof

Study Record Dates

First Submitted

October 29, 2024

First Posted

November 12, 2024

Study Start

December 1, 2024

Primary Completion

November 1, 2025

Study Completion

November 1, 2025

Last Updated

November 12, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share